203 related articles for article (PubMed ID: 25251158)
1. Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice.
Roti Roti EC; Ringelstetter AK; Kropp J; Abbott DH; Salih SM
PLoS One; 2014; 9(9):e108174. PubMed ID: 25251158
[TBL] [Abstract][Full Text] [Related]
2. Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice.
Kropp J; Roti Roti EC; Ringelstetter A; Khatib H; Abbott DH; Salih SM
PLoS One; 2015; 10(11):e0142588. PubMed ID: 26544188
[TBL] [Abstract][Full Text] [Related]
3. Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.
Roti Roti EC; Leisman SK; Abbott DH; Salih SM
PLoS One; 2012; 7(8):e42293. PubMed ID: 22876313
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
Salih SM; Ringelstetter AK; Elsarrag MZ; Abbott DH; Roti EC
Biol Reprod; 2015 Mar; 92(3):73. PubMed ID: 25609833
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.
Roti Roti EC; Salih SM
Biol Reprod; 2012 Mar; 86(3):96. PubMed ID: 22190700
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy.
Skaznik-Wikiel ME; McGuire MM; Sukhwani M; Donohue J; Chu T; Krivak TC; Rajkovic A; Orwig KE
Fertil Steril; 2013 Jun; 99(7):2045-54.e3. PubMed ID: 23453120
[TBL] [Abstract][Full Text] [Related]
7. Ovarian damage from chemotherapy and current approaches to its protection.
Spears N; Lopes F; Stefansdottir A; Rossi V; De Felici M; Anderson RA; Klinger FG
Hum Reprod Update; 2019 Nov; 25(6):673-693. PubMed ID: 31600388
[TBL] [Abstract][Full Text] [Related]
8. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-induced ovarian toxicity.
Ben-Aharon I; Bar-Joseph H; Tzarfaty G; Kuchinsky L; Rizel S; Stemmer SM; Shalgi R
Reprod Biol Endocrinol; 2010 Mar; 8():20. PubMed ID: 20202194
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin.
Morgan S; Lopes F; Gourley C; Anderson RA; Spears N
PLoS One; 2013; 8(7):e70117. PubMed ID: 23922929
[TBL] [Abstract][Full Text] [Related]
11. Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin‑releasing hormone agonist.
Ma N; Chen G; Chen J; Cui M; Yin Y; Liao Q; Tang M; Feng X; Li X; Zhang S; Ma D; Chen G; Li K; Ai J
Oncol Rep; 2020 Nov; 44(5):1917-1928. PubMed ID: 33000247
[TBL] [Abstract][Full Text] [Related]
12. How do chemotherapeutic agents damage the ovary?
Morgan S; Anderson RA; Gourley C; Wallace WH; Spears N
Hum Reprod Update; 2012; 18(5):525-35. PubMed ID: 22647504
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin obliterates mouse ovarian reserve through both primordial follicle atresia and overactivation.
Wang Y; Liu M; Johnson SB; Yuan G; Arriba AK; Zubizarreta ME; Chatterjee S; Nagarkatti M; Nagarkatti P; Xiao S
Toxicol Appl Pharmacol; 2019 Oct; 381():114714. PubMed ID: 31437492
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27
Jang H; Na Y; Hong K; Lee S; Moon S; Cho M; Park M; Lee OH; Chang EM; Lee DR; Ko JJ; Lee WS; Choi Y
J Pineal Res; 2017 Oct; 63(3):. PubMed ID: 28658519
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients.
Codacci-Pisanelli G; Del Pup L; Del Grande M; Peccatori FA
Crit Rev Oncol Hematol; 2017 May; 113():90-96. PubMed ID: 28427528
[TBL] [Abstract][Full Text] [Related]
16. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
Brüning A; Burger P; Vogel M; Rahmeh M; Friese K; Lenhard M; Burges A
Invest New Drugs; 2009 Dec; 27(6):543-51. PubMed ID: 19039521
[TBL] [Abstract][Full Text] [Related]
19. Diminished Ovarian Reserve Chemotherapy-Induced Mouse Model: A Tool for the Preclinical Assessment of New Therapies for Ovarian Damage.
Buigues A; Marchante M; Herraiz S; Pellicer A
Reprod Sci; 2020 Aug; 27(8):1609-1619. PubMed ID: 32430713
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced damage to ovary: mechanisms and clinical impact.
Bedoschi G; Navarro PA; Oktay K
Future Oncol; 2016 Oct; 12(20):2333-44. PubMed ID: 27402553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
